Prognostic factors for recurrence and survival in uncommon variants of vulvar cancer.

dc.contributor.authorZapardiel, Ignacio
dc.contributor.authorGracia, Myriam
dc.contributor.authorDíez, Javier
dc.contributor.authorBuda, Alessandro
dc.contributor.authorNoya, Maria C
dc.contributor.authorIaco, Pierandrea De
dc.contributor.authorVieira-Baptista, Pedro
dc.contributor.authorIacoponi, Sara
dc.contributor.authorVULCAN Study collaborative group
dc.date.accessioned2025-01-07T12:44:48Z
dc.date.available2025-01-07T12:44:48Z
dc.date.issued2020-10-16
dc.description.abstractTo analyze the prognostic factors of recurrence and overall survival in rare histotypes of vulvar cancer. An international multicenter retrospective study including patients diagnosed with vulvar cancer was performed. One hundred centers participated in the study and 2453 vulvar cancer cases were enrolled from January 2001 until December 2005. After exclusion of squamous vulvar cancer, Paget´s disease and vulvar melanoma 112 tumors were analyzed for the present study. The mean age at diagnosis was 64.9 ± 17.2 years. 99 (88.4%) patients had a single lesion, in 25 (22.3%) cases the vulvar tumor involved the midline, and only 13 (11.5%) patients had clinically positive inguinal lymph nodes. The mean size of the lesion was 33.8 ± 33.9 mm. Regarding the surgical treatment, 2 (1.8%) patients underwent skinning vulvectomy, 63 (56.3%) local excision, 41 (36.6%) vulvectomy, 3 (2.7%) exenteration and 3 (2.7%) did not receive any surgical treatment. The mean free surgical margin was 8.2 ± 9 mm and 7 (6.2%) patients presented positive inguinal nodes. Radiotherapy was administered in 22 (19.6%) patients and it was performed postoperatively in all cases; 14 (12.5%) patients received adjuvant chemotherapy. The mean overall follow-up time was 44.1 ± 35.7 months. The risk factors associated with overall survival were chemotherapy and radiotherapy, tumor size and stromal invasion (p  Postoperative radiotherapy seems to be the only independent factor associated with recurrence and overall survival in uncommon types of vulvar cancer.
dc.identifier.doi10.1007/s00404-020-05813-x
dc.identifier.essn1432-0711
dc.identifier.pmid33067709
dc.identifier.urihttps://hdl.handle.net/10668/24896
dc.issue.number3
dc.journal.titleArchives of gynecology and obstetrics
dc.journal.titleabbreviationArch Gynecol Obstet
dc.language.isoen
dc.organizationSAS - Hospital Universitario Torrecárdenas
dc.page.number759-766
dc.pubmedtypeJournal Article
dc.subjectInguinal lymphadenectomy
dc.subjectPrognostic factors
dc.subjectUncommon tumors
dc.subjectVULCAN study
dc.subjectVulvar cancer
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLymph Node Excision
dc.subject.meshLymph Nodes
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Factors
dc.subject.meshTreatment Outcome
dc.subject.meshVulvar Neoplasms
dc.subject.meshVulvectomy
dc.titlePrognostic factors for recurrence and survival in uncommon variants of vulvar cancer.
dc.typeresearch article
dc.volume.number303

Files